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Indiscriminate use of conventional antibiotics has led to the development of 
resistance by various strains of bacteria and fungi against majority of drugs currently 
in use. Hence the need to develop alternative strategies for combating these 
microbial infections is highly pertinent and relevant to the field of medicinal therapy 
and healthcare development. Antimicrobial peptides (AMPs) are one such promising 
candidate, owing to their broad spectrum of activity and unique mechanisms of 
action, which renders it difficult for the pathogen to develop resistance against them. 
Ideally, such antimicrobial peptides should selectively target microbial membranes 
without affecting the host mammalian cells. 
 This study aims to develop a new synthetic antimicrobial amphiphilic peptide to 
target different bacteria and fungi without causing appreciable cytotoxicity.  The first 
part of the thesis deals with the design and chemical synthesis of a polyunsaturated 
fatty acid conjugated peptide. Several characterization techniques were used to 
confirm the successful conjugation of the fatty acid to the peptide and to understand 
its functional attributes. A control amphiphilic peptide which differs only in the 
degree of unsaturation of the fatty acid was similarly synthesized and characterized. 
The two peptides were also found to self-assemble in solution forming nanoparticles. 
The next part of the thesis describes the in vitro studies done to test the biological 
activity of the synthetic amphiphilic peptides. The minimum inhibition concentration 
assay was performed against pathogenic organisms like Staphylococcus aureus and 
Candida albicans. The cytotoxicity of the two amphiphilic peptides was also tested by 
means of the haemolysis assay against rat red blood cells. The conjugation of the 
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polyunsaturated fatty acid to the peptide improved its antimicrobial activity without 
compromising on its haemolytic activity.  
In conclusion, the polyunsaturated fatty acid-peptide conjugate could be used as a 
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Infectious diseases are diseases caused by bacteria and other organisms which can 
spread by different means. According to The global burden of diseases update of 
2004 by the World Health Organization (WHO), infectious and parasitic diseases are 
the second most leading cause of death in the world after cardiovascular disease [1].  
For example, in 2009, around 2.8 million cases of tuberculosis were reported in the 
African region alone, out of which 0.4 million cases resulted in mortality as shown in 
Table 1 [2]. The data also indicates that around 65% of the globally incident cases 
occurred in the African and South Asian region during that period. This distribution of 
mortality due to infectious diseases is particularly more relevant with respect to the 
developing nations in the African and certain regions of the Asian continent. In these 
regions, the incidence of communicable diseases is quite high and often epidemic in 
nature, owing to several factors like poor hygiene and sanitation, shortage of proper 
medical care and facilities, overpopulation etc.  
On the other hand, though the burden of communicable diseases in the developed 
countries is less, their spread and impact in such countries cannot be trivialized as is 
evident from the statistics from Table 1.  Problems associated with prevalence of 
communicable diseases in developed countries are usually of a different nature, often 
associated with complications arising due to improper practises followed during 




Table 1: Estimated Tuberculosis incidence, prevalence and mortality region wise for the year 2009 [2]. 
 
One such problem is that of multi drug resistance (MDR). Treatment of infectious 
diseases typically involves chemotherapy, with antibiotics being conventionally used 
since the 1940s, although alternative forms of therapy like gene therapy [3], vaccines 
[4] and phage therapy [5] have also been used and extensively studied. Several classes 
of antibiotics have been developed over the years and they cover a wide range of 
chemical compounds like sugars (ex: Aminoglycosides) [6], glycopeptides                  
(ex: Vancomycin) [7], sulphonamides etc. However the indiscriminate use of these 
antimicrobial drugs in recent years, especially in developed countries, has led to the 
development of antibiotic resistance among various strains of bacteria and fungi [8].  
This further escalates the problem, as existent drugs no longer remain effective in 
 




















Africa 2 800 30%  340 3 900  450  430  50 
The Americas  270 2.9%  29  350  37  20 2.1 
Eastern 
Mediterranean  660 7.1%  110 1 000  180  99  18 
Europe  420 4.5%  47  560  63  62  7 
South-East 
Asia 3 300 35%  180 4 900  280  480  27 
Western 
Pacific 1 900 21%  110 2 900  160  240  13 
Global total 9 400 100%  140 14 000  164 1 300  19 
1 Incidence is the number of new cases arising during a defined period.  
2 Prevalence is the number of cases (new and previously occurring) that exists at a given point in 
time.  
3 Pop indicates population. 
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controlling the spread of such deadly infections. Hence, development of alternative 
strategies for restricting the growth of drug resistant microbes has become the need 
of the hour. 
1.2 Objective 
Antimicrobial peptides (AMPs) are a class of compounds found inherently as part of 
the innate host defense system in many animals and plants. These are increasingly 
seen as an alternative to standard antibiotics, as their ability to directly attack the 
microbial membrane renders it more difficult for the microbes to develop resistance 
against them. This research mainly focuses on the development of a polyunsaturated 
fatty acid conjugated peptide to selectively target pathogenic bacteria and fungi 
without causing harm to normal host cells. With this main objective, the scope of the 
work is further divided into two parts: 
1) Design, synthesis and physico-chemical characterization of a new synthetic 
amphiphilic peptide for targeting microbes. 
 The first part of the work deals with material synthesis and characterization. A new 
synthetic polyunsaturated fatty acid conjugated peptide was designed to form an 
amphiphilic molecule so as to improve the antimicrobial properties of the native 
peptide (non-conjugate). A saturated amphiphilic peptide analogue was also designed 
and synthesized as a control. The amphiphilic peptides were further characterized by 
techniques like Matrix assisted laser desorption ionization – Time of flight (MALDI-
TOF), Proton nuclear magnetic resonance (1H-NMR), Critical micelle concentration 
(CMC) measurement and particle size analysis by Dynamic light scattering.  
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2) In vitro structure-activity relationship comparison between the unsaturated 
and saturated amphiphilic peptides.  
Following the synthesis and characterization of the amphiphilic peptides, the second 
part of this thesis is focused on the in vitro antimicrobial performance of the 
amphiphilic peptide conjugates synthesized earlier. First, the bacteriostatic minimum 
inhibitory concentration (MIC), i.e., the minimum concentration of the amphiphilic 
peptides required to inhibit microbial growth was determined against Gram-positive 
bacteria Bacillus subtilis, S.aureus, Gram-negative bacteria Escherichia coli, 
Pseudomonas aeruginosa and Yeast C.albicans. The structure-activity relationship of 
these antimicrobial peptides was evaluated by comparing the antimicrobial 
performance of the native peptide, and the corresponding saturated and unsaturated 
fatty acid conjugated amphiphilic peptides. Further, concentration dependent killing 
curve analysis was performed to test the potency of the polyunsaturated fatty acid-
peptide conjugate in killing microbial cells, instead of just merely inhibiting their 
growth. Finally, the selectivity of the amphiphilic peptide conjugates in killing 
microbial cells was tested by analysing their MIC in relation to their corresponding 
haemolytic properties. For this, the haemolysis assay against rat red blood cells was 






2. LITERATURE REVIEW 
Nearly seventy years since the discovery of antibiotics, we still remain in constant 
threat of bacterial and fungal diseases like tuberculosis, meningitis etc. The 
continuous emergence of newer deadly strains of bacteria and fungi can be attributed 
to the ability of these microbes to quickly adapt to antibiotics to counter the effects 
of antimicrobial drugs. Hence, a deeper understanding of the membrane structure of 
these pathogens, along with knowledge of the bacterial resistance development 
mechanisms would aid in developing newer therapeutics. 
In this chapter, a brief outline of the main methodologies adopted in the treatment of 
pathogenic infections would be elucidated. The main challenges and issues involved 
in combating microbial diseases would also be discussed. Further, the recent 
advances in the development of therapeutics for the same would be elaborately 
described. Special emphasis would be laid on the use of antimicrobial peptides as 
potential therapeutic drugs along with a discussion on the mechanism of action and 
the factors affecting the activity of these AMPs towards bacterial and fungal 
membranes. 
2.1 Bacterial and fungal infections –An overview 
Infectious disease is any change from a state of health in which part or all of the host 
body is not capable of carrying on its normal functions due to the presence of an 
organism or its products [9]. Organisms which typically cause these infections include 
bacteria, fungi, viruses and protozoa. Transmission of these infections usually occurs 
through physical contact, body fluids, air, water, soil, contaminated food, vectors etc.  
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Briefly described below is the epidemiology of a few life-threatening contagious 
diseases.  
2.1.1 Tuberculosis 
Tuberculosis is a common and often lethal infection caused by Mycobacterium 
tuberculosis. This bacterium usually attacks the lungs and typical symptoms include 
coughing with blood spattered sputum, fever and weight loss. The discovery of 
isoniazid and other drugs led to the improvement in tuberculosis cure. However it   
re-emerged in the 1980s with the advent of HIV/AIDS, stimulating the spread of 
latent Mycobacterium tuberculosis amongst other healthy individuals too. The WHO 
evaluates that the incidence of tuberculosis in African countries increased by more 
than two fold from 1990 to 2005 [10]. Also, the prevalence of tuberculosis is more 
pronounced in HIV infected patients and ultimately causes death in around 30 to 40 
percentage of such cases [11]. Tuberculosis is associated with hygiene, sanitation and 
crowding and hence its control is a serious problem in highly populated areas, 
especially developing countries living in poverty. 
2.1.2 Meningitis 
Another fatal illness is meningitis, which is a bacterial infection and attacks the brain 
tissues. It causes inflammation of the meninges, the covering of the brain and spinal 
cord. Some of the major organisms responsible for this disease include Neisseria 
meningitidis, Haemophilus influenzae type b and Streptococcus pneumoniae.               
S. aureus has also been known to induce meningitis in some cases [12]. Typical 
symptoms include stiff neck, high fever, headaches, vomiting and sensitivity to light. 
Meningitis causes death in many cases and is also associated with long time 
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morbidity, causing permanent effects like hearing loss, brain damage and renal failure 
[13]. Around 4100 cases of bacterial meningitis were reported in the United States of 
America alone, in between 2003-2007, and 500 among them were fatal [14].  The 
methodology of treatment varies with the type of organism responsible for causing 
the infection. Treatment for meningitis is even more difficult compared to other 
common infectious diseases like tuberculosis or cholera, because the bactericidal 
activity of the drug depends on the level of penetration of the drug through the blood 
brain barrier and concentration in the cerebrospinal fluid.  
2.1.3 Pneumonia 
Pneumonia is a respiratory infection causing inflammation of the lung alveoli. It can 
be caused by viruses (adenoviruses, influenza virus), bacteria (Streptococcus 
pneumonia, S.aureus, H.influenza etc.), fungi (Histoplasma capsulatum, Cryptococcus 
neoformans etc.) and parasites. It is a common disease found spanning across all 
ages, though more prevalent in children. It is the sixth leading cause of death in the 
United States and the most common cause of death due to infectious diseases. 
Cough, chest pain, fever and difficulty in breathing are characteristic symptoms. 
Penicillin and amoxicillin are administered in case of infections by S.pneumonia, 
though several strains are rapidly becoming resistant to penicillin. Erythromycin can 
also be used. Newer macrolides and fluoroquinolones are used in cases of infection 
by H.influenza. With the rise of drug resistant strains, the treatment of pneumonia is 
becoming much more difficult. 
Having reviewed the current state of some of the major deadly human infections, it is 
evident that the peril of these microbial infections is a persistent problem and cannot 
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be eradicated that easily. Hence it becomes necessary to identify and comprehend 
the various intricacies and complications involved in preventing the incidence and 
spread of such communicable diseases. In this regard, the first step is to understand 
better, the root cause of the occurrence of such infections – pathogenic microbes. An 
extensive study of the morphology and mechanism of action of these causative 
pathogens would bring us a step closer in combating this vital health issue. The 
following section would elaborate on the basic physiology of two of the most 
common pathogens: bacteria and fungi. 
2.2 Morphology and Structure of pathogens – A perspective 
2.2.1 The Bacterial Cell 
Bacteria are single-celled prokaryotic organisms without a distinct nucleus.  They are 
either spherical (cocci), rod shaped (bacillus) or variable in shape (pleomorphic).  
Bacterial plasma membranes have a higher proportion of proteins in comparison to 
eukaryotic cells due to the enormous amount of functions performed by them. 
Bacterial membranes also lack cholesterols as compared to eukaryotic cells. 
Prokaryotic cytoplasm does not contain complex membranous organelle. Also, they 
lack a membrane-delimited nucleus and all the genetic material is enclosed inside an 
irregular shaped region called the nucleoid.  
Bacteria can be divided into Gram-positive and Gram-negative according to their 
ability to retain the Gram stain which was first reported by Christian Gram.  Gram- 
positive bacteria turn purple in colour due to retention of crystal violet in the 
peptidoglycan layer on counterstaining with safranin. On the other hand, Gram- 
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negative bacteria turn red in colour due to washing away of crystal violet on account 
of damage of its outer lipopolysaccharide (LPS).  This test suggests that certain basic 
differences exist between Gram-positive and Gram-negative bacteria which help to 
distinguish between them. This distinction is also useful in selectively targeting 
bacteria, as many of the drugs that are currently in use function by disruption of the 
bacterial cell membrane. 
2.2.1.1 Morphology of the Gram-negative bacteria 
The Gram-negative cell envelope can be divided into the outer membrane, a 
peptidoglycan cell wall and the cytoplasmic or inner membrane.  
The outer membrane is found only in the Gram-negative bacteria and is a lipid bilayer 
consisting mainly of glycolipids especially lipopolysaccharide (LPS). LPS is a negatively 
charged molecule made up of lipid A, eight to twelve variable sugar units and three to 
eight phosphate residues attached to O antigen.  
The peptidoglycan layer is a rigid layer giving a firm structure and shape to the 
bacteria. It is composed of repeating units of disaccharide N-acetyl glucosamine-         
N-acetyl muramic acid cross-linked by pentapeptide chains. The outer membrane is 
attached with the peptidoglycan layer by means of a lipoprotein called Braun’s 
protein.  
The periplasm is an aqueous space interspersed between the inner membrane and 
outer membrane. It is densely packed with proteins.  
The inner membrane is a phospholipid bilayer which contains proteins necessary for 
most of the cellular processes like energy production, lipid synthesis etc.  
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2.2.1.2 Morphology of the Gram-positive bacteria 
The Gram-positive bacteria, on the other hand, lack an outer membrane. The cell wall 
consists of a single peptidoglycan or murein layer. They also possess large amounts of 
long polymeric techoic acids made of glycerol phosphate, glucosyl phosphate or 
ribitol phosphate monomers. Techoic acids provide the anionic surface for the Gram 
positive bacteria as they are negatively charged and are of two types: wall techoic 
acids which are attached to the peptidoglycan and lipotechoic acids that are 
connected to the cell membrane. These differences in composition of the cell 
membrane can be exploited by antimicrobial agents to selectively target specific 
bacteria. 
2.2.2 The Fungal Cell 
Fungi are eukaryotic organisms with rigid cell walls made up of chitin. Their basic 
cellular unit is called hypha which contains the membrane bound nucleus, 
mitochondria, Golgi apparatus and ribosomes. The cell membranes are zwitterionic in 
nature and are rich in sterols like ergosterol. The fungal cell wall enables it to 
withstand turgor pressure and is highly essential for its survival. Here, the cell wall 
composition is discussed with respect to a representative fungus, C. albicans. 
Approximately 80 to 90 % of the cell wall of C. albicans is carbohydrates which 
include β-glucans, chitin and mannans. The first two components provide the 
mechanical strength to the wall while mannans form the major part of the cell wall 
matrix. The overall structure of the cell wall arises due to the covalent, hydrophobic 
and hydrogen bonds between these components. 
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2.2.3 Comparison of lipids in prokaryotic and eukaryotic membranes – A means of 
selective activity  
Majority of biomembranes are made of phospholipid bilayers. However the 
membrane compositions vary significantly between eukaryotic and prokaryotic cells. 
Some of the lipids found in natural cell membranes include the negatively charged 
phosphatidyl glycerol (PG), cardiolipin (CL), phosphatidylserine (PS) and the neutrally 
charged phosphatidylcholine (PC), phosphatidylethanolamine (PE) and sphingomyelin 
(SM). Membranes composed primarily of PG, CL and PS possess a net negative charge 
and are predominantly found in bacterial cells while zwitterionic phospholipids like 
PC, PE and SM are found in eukaryotic cells. Sterols present in membranes can further 
distinguish between mammalian cells and fungal cells. The cytoplasmic surface of 
erythrocytes possesses PE and anionic lipids while the extracellular monolayer is 
composed essentially of SM [15]. This varied lipid composition is responsible for the 
selective action of various membrane disruptive antimicrobial agents [16].  
2.3 Challenges facing the control of infectious diseases 
Before the advent of antibiotics, most of the life threatening diseases were caused by 
infections due to bacteria and fungi and there was little progress towards their 
treatment. The discovery of penicillin by Alexander Fleming changed the world’s 
perspective towards treating bacterial infections. Hence, the 1940s and 1950s saw a 
surge of antibiotics being developed to tackle these deadly infections.  However the 
large cost of research and difficulty in constantly developing newer drugs to counter 
bacterial resistance discouraged the major pharmaceutical companies from pursuing 
further research in this area. Between 1962 and 2000, no new class of antibiotics 
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were discovered [17]. However in the meantime, numerous strains of bacteria and 
fungi developed resistance to existing antibiotics, thereby escalating the menace of 
infectious diseases. Currently existing strategies to confront such infections typically 
involve development of newer therapeutics, increasing the life of existing antibiotics, 
usage of vaccines and improved hygiene and sanitation. However, the continued 
adaptation of bacteria and fungi to these various control strategies is a matter of 
grave concern.  As a result, today, the need to develop newer therapeutics to combat 
multi-drug resistance has become extremely pertinent and is the most obvious 
solution to the problem. 
Microbial resistance is the ability of bacteria and other microorganisms to endure the 
attack of various drugs and antibiotics intended to kill them by constant 
acclimatization and mutation. Inappropriate use of antibiotics is a growing concern 
for resistance development. Also, employment of antimicrobial agents for uses other 
than therapeutic reasons is hastening the emergence of antimicrobial resistance. 
Resistance can appear in a matter of months to even years [18]. One of the early 
reports of resistance of S.aureus towards penicillin was reported by Bailey and 
Cavallito in 1947 where S.aureus developed resistance quickly against penicillin and 
streptomycin [19]. Over the years, various resistant strains of S.aureus have emerged 
including methicillin resistant Staphylococcus aureus (MRSA), gentamicin resistant     
S. aureus and streptomycin resistant S.aureus. MRSA has become a common hospital 
infection and vancomycin is often used as a last resort to counter such infections 
when other antibiotics fail. However in recent years, vancomycin resistant strains of 
bacteria have also emerged, leading to the usage of other alternatives like linezolid 
[20]. Since bacteria are characteristic of a rapid generation time, even a single 
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mutation can spread quickly through the population thereby accelerating the process 
of development of resistance. The rapid spread of antibacterial resistance genes 
occurs because they get accumulated on plasmids that are replicated and passed 
between bacterial cells. For effective antibiotic action, they must reach their specific 
bacterial targets and accumulate at appropriate concentrations to act within a 
reasonable time. However, if the antibiotic is pumped out sooner enough, the 
concentration inside the bacteria isn’t sufficient enough to affect the bacterial cells. 
These pumps are modified forms of membrane pumps that are found in bacteria to 
transport lipophilic or compounds in and out of the cell [18]. Another strategy 
adopted by bacteria is to destruct the attacking molecule of the antibiotic. One such 
instance is the cleavage of the β-lactam ring of penicillins by β-lactamase enzyme 
produced by resistant bacteria [18]. Also, resistant bacteria can camouflage or 
reprogram the target. 
By circumventing these mechanisms, new antibiotics can thus be tailored and 
designed to overcome the resistance machinery of these pathogens. The next section 
briefly discusses the existing and emerging technologies and drugs available to target 
various bacterial and fungal infections. 
2.4 Antimicrobial agents and their mode of action 
2.4.1 Antibiotics 
Antibiotics are among the first forms of medication utilized to treat microbial 
infections. These involve a wide variety of molecules capable of attacking different 
processes and parts of the microbial cell.  Antibiotics can be broadly classified into    
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β-lactams, glycopeptides, macrolides, sulphonamides, aminoglycosides, quinolones, 
tetracycline and oxazolidinones. Briefly described below are some of the 
conventional antibiotics in use currently. 
2.4.1.1 β-lactams 
β-lactams like penicillin, cephalosporins, carbanapems etc. contain a characteristic   
β-lactam ring and interfere with cell wall synthesis by inhibiting the enzymes 
necessary for peptidoglycan layer synthesis. Adjacent peptide strands connected by 
amide linkages provide stability to the peptidoglycan layer of the bacterial cell wall 
through the action of transpeptidases. These are hence the target sites for β-lactam 
antibiotics which act by acylating the active sites of transpeptidases [21], [22]. This 
then causes the ring to open and the penicilloylated transpeptidases occupy the 
natural binding sites thereby inhibiting cell wall synthesis. However several strains of 
bacteria like staphylococci have now become resistant to β-lactams, thereby leading 
to the use of glycopeptides like vancomycin. 
2.4.1.2 Glycopeptide antibiotics 
This class of antibiotics includes vancomycin, teicoplanin and ramoplanin. They are 
also involved in the inhibition of bacterial cell wall peptidoglycan synthesis. However 
unlike β-lactams, they target the peptide substrate for enzyme binding and prevent it 
from interacting with the transpeptidases that catalyse the transglycosylase reaction. 
Vancomycin acts by forming five hydrogen bonds with D-Ala –D-Ala dipeptide of each 
uncross-linked peptidoglycan pentapeptide side chain and hence preventing the 




Macrolides are a group of antibiotics containing a macrocyclic lactone ring of 12 or 
more members. The 14, 15 and 16 membered macrolides are conventionally used as 
antibiotics [23]. They possess antimicrobial activity against gram positive bacteria. 
Erythromycins and azythromycins belong to this group of antibiotics. These act by 
inhibiting protein synthesis in bacteria by attacking the 50S ribosome protein and 
either blocking the protein translation initiation or translocation of peptidyl tRNAs 
[24]. 
2.4.1.4 Tetracyclines 
Tetracyclines comprise of a linear tetracyclic nucleus to which several functional 
groups are attached. They inhibit bacterial protein synthesis by preventing the 
association of aminoacyl tRNA with the bacterial ribosome [25]. These are broad 
spectrum antibiotics, being potent against a variety of Gram-positive and Gram- 
negative bacteria.  
Hence it can be seen that since antibiotics target specific functions in specific 
bacteria, it is easier to develop resistance against them. Therefore, development of 
alternate medicines is highly essential to keep up with the rapid acquisition of 
microbial drug resistance. The next section discusses some of the alternative modes 
of therapy for combating infectious diseases and multi-drug resistance. 
2.4.2 Alternate strategies for treatment of Infectious diseases 
It is now clear that the engineering of new technologies and strategies to combat 
communicable diseases is the need of the hour. Some of the potential emerging 
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technologies include phage therapy, gene therapy, vaccination as well as 
development of alternate drugs like antimicrobial peptides or antimicrobial polymers, 
etc.  
Bacteriophages are bacterial viruses that invade bacterial cells and disrupt bacterial 
metabolism. They have been found to be effective than antibiotics in treating drug 
resistant bacteria [26].  However their use has been restricted owing to a few clinical 
failures and the widespread use of antibiotics.  
Gene therapy involves the introduction of new genes into cells of an individual to 
treat diseases. In the domain of infectious diseases, this refers to strategies based on 
nucleic acids, proteins and immunotherapeutic approaches [3]. It is an emerging 
technique and gene therapy models have evolved in various diseases like AIDS [27], 
pneumonia [28] etc.  
Apart from the above mentioned strategies, a main approach used to target microbial 
resistance is the development of newer, robust and alternative therapeutic drugs. In 
this regard, antimicrobial peptides are a promising class which are increasingly being 
studied for their antimicrobial action. The next part of the thesis deals with 
antimicrobial peptides and their mode of action against various bacteria and fungi.  
2.5 Antimicrobial Peptides 
The innate immune system of most animals provides protection against invading 
pathogens. In addition to the skin and the mucous membrane, the host-defence 
system also produces chemical molecules to prevent the entry of micro organisms. 
Antimicrobial peptides are one such class of compounds, found either as structural 
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components or induced in response to an infection. Antimicrobial peptides can be 
generally classified into natural and synthetic analogues. Around 1228 antimicrobial 
peptides have been registered in the latest updated antimicrobial peptide database 
[29]. AMPs have gained immense interest in recent years as a potential therapeutic to 
substitute traditional antibiotics. The following sections would highlight the major 
advancements in the area of antimicrobial peptides. A comprehensive review of the 
classification, mechanism of action and the methodologies adopted to improve the 
biological activity of these AMPs would be provided. This will enable to realize the 
potential of antimicrobial peptides as an appropriate substitute for conventional 
antibiotics. 
2.5.1 Natural antimicrobial peptides 
Natural AMPs are molecules found inherently in various parts of the host like skin, 
macrophages, neutrophils, leukocytes etc. AMPs have been isolated from various 
vertebrates and invertebrates as well as from plants. They are commonly extracted 
from amphibians or insects or even humans. Briefly described below are some of the 
classes of natural antimicrobial peptides. 
Linear cationic-alpha helical peptides are one of the most common AMPs found in 
nature. This group consists of short peptides with a cationic charge and capable of 
forming α-helix structure. The positive charge helps to electrostatically attach to the 
anionic membranes of bacteria and form an α-helix in the presence of a membrane, 
thereby facilitating further penetration into the bacterial membrane. Some of the 
peptides belonging to this class include cecropins, magainin, dermaseptin etc. 
Cecropins were first discovered and isolated from hyalophora cecropia (giant silk 
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moth) in 1981 by Boman et al [30]. Cecropins contain around 31-39 amino acid 
residues with an aromatic residue at position two of the peptide amino acid sequence 
which is necessary for antimicrobial activity. They are known to possess activity 
against majority of Gram negative bacteria and a few select Gram positive bacteria.  
Anionic peptides are a group of peptides that were only recently discovered. These 
are usually peptides with a negative charge and are also amphiphilic in nature. 
However, the mechanism of action of this group of peptides isn’t understood clearly 
yet. Some of the peptides in this category include dermicidins and maximin H5. 
Dermicidins are peptides expressed by human sweat glands and transported to the 
epidermal surface [31]. Maximin H5 is another anionic peptide extracted from toad 
skin [32]. These peptides have been found to kill a variety of bacteria and more 
specifically S.aureus.  
Another class contains peptides which are rich in specific amino acids and are usually 
linear in structure. These peptides generally lack cysteine. Some of the peptides in 
this category include bactenicins which are rich in proline residues and indolicidin 
which are rich in tryptophan residues. Indolicidin is a cationic AMP extracted from 
bovine neutrophils. It contains 13 amino acids and attacks the cytoplasmic membrane 
by forming channels [33]. 
Peptides containing cysteine residues, forming disulphide bonds include the group of 
peptides called defensins. Defensins were first derived from human neutrophils by 
Tomas Ganz et al [34]. Defensins are cysteine rich cationic peptides and are stabilized 
by three intramolecular disulphide bonds. The defensins are of three types:                 
α defensins, β defensins and θ defensins, which differ in the disulphide linkages [35]. 
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Defensins possess activity against a variety of bacteria, fungi and virus and they act by 
permeabilizing the cytoplasmic membrane [35].  
2.5.2 Mechanism of action of antimicrobial peptides [15],[36] 
The mechanism of action of antimicrobial peptides is not fully understood and still 
remains an area that is being widely studied. It was originally thought that microbial 
membranes were the only target of AMPs. However alternate means of attack have 
also been discovered and multiple cell targets also exist. Nevertheless, for majority of 
AMPs, the primary target remains the cell membrane of the pathogens.  The first 
means of attachment on to the bacterial membrane is usually by means of an 
electrostatic attraction between the anionic or cationic AMPs with molecules or 
structures on the bacterial surface. This attachment is much stronger if the peptide 
possesses a greater number of cationic residues like lysine and arginine. After this 
initial binding, further modes of action can be described by means of three distinct 
mechanisms whereby the AMPs attack the cytoplasmic membrane: 
2.5.2.1 The Carpet model 
If the ratio of peptide to lipid is low, then the peptide gets oriented parallel to the 
surface forming a ‘carpet’. This is due to multiple electrostatic interactions with 
anionic phospholipid headgroups. The presence of these negatively charged lipids 
helps to reduce the repulsive forces between the peptide cationic charges, thereby 
forming a dense peptide layer. Membrane disruption then occurs due to 
unfavourable energetics. Hence it doesn’t involve pore formation and membrane 
disruption isn’t necessarily related to membrane penetration. Cecropins have been 
found to attack bacterial membranes by this mechanism [37]. 
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2.5.2.2 The Barrel-Stave model 
In this, the peptide helices are arranged in the form of a barrel inside the lipid bilayer. 
The hydrophobic region of the peptide is aligned with that of the lipids of the bilayer, 
while the hydrophilic residues of the peptide are arranged to form the interior of the 
barrel. Upon binding, the peptide undergoes phase conformational transition aiding 
the insertion of the hydrophobic component of the peptide into the membrane. 
Beyond a critical concentration, the peptide forms aggregates and inserts deeper into 
the membrane. This mechanism is not widely found among AMPs. Such a mechanism 
has been proposed for almathecin and ceratotoxin A [38] [39] .  
2.5.2.3 The toroid pore model 
This is one of the most extensively studied mechanisms of AMP action. According to 
this model, the AMPs insert well into the membrane and cause the lipid monolayers 
to twist and bend continuously so as to make the water core lined by both the 
peptides and the lipids. The polar heads of the peptides interact with their 
counterpart polar groups in the lipids. The alpha helices orient on the surface of the 
membrane and the hydrophobic residues displace the polar heads and disrupt the 
hydrophobic region causing strain in the membrane. At a threshold concentration, 
these helices then orient perpendicular to the membrane and begin to self associate 
forming the toroidal pore complex. The mode of action of peptides like magainin can 





2.5.2.4 Alternate methods of action 
Not all AMPs permeabilize the bacterial membrane, but they can still cause cell death. 
This is because they cause disruption of other cellular processes and structures. There 
are increasing evidences that multiple targets of action exist for AMPs as in the case 
of Cecropin A, where, though the major mechanism of action seems to be membrane 
disruption, it has also been found to affect gene transcription levels in E.Coli [41].  This 
might probably explain the reason behind the difficulty in developing resistance 
against AMPs as they exhibit unique modes of action as well as multiple targets of 
action. Alternate targets might involve interaction with nucleic acids, proteins or 
disruption of protein folding etc. For example indolicidin, an AMP from bovine 
neutrophils has been found to inhibit DNA synthesis in E.Coli without causing lysis of 
the bacterial membrane [42]. Similarly pyrrhocoricin interferes with protein folding by 
diminishing the activity of ATPase of recombinant DnaK [43]. Some peptides have also 
been found to disrupt cell wall synthesis like the AMP nisin which targets lipid II 
crucial in the cell wall biosynthesis of bacteria [44] .  
2.5.3 Synthetic antimicrobial peptides  
This consists of a variety of peptides which are designed based on the sequences of 
the above mentioned natural peptides and are synthesized chemically. Typically the 
systematic design of synthetic AMPs starts with a natural AMP as the prototype and 
further modifications and optimizations are done to enhance the antimicrobial 
activity of these peptides without causing appreciable cytotoxicity to mammalian 
cells. This might involve either changing the amino acid sequence [45],[46] or 
chemically conjugating various moieties to the peptide to improve its antimicrobial 
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activity [47],[48]. The following section elucidates some of the major factors to be 
considered while designing AMPs. 
2.5.4 Factors affecting antimicrobial activity of peptides 
Several properties have been found to influence the antimicrobial activity of 
peptides. Prominent among them are cationic charge, hydrophobicity and 
amphipathicity, secondary structure.  These properties are directly related to the 
structure and composition of the cell membrane of bacteria and fungi. A few of these 
properties and their effects are discussed in the following paragraphs. 
2.5.4.1 Cationic charge 
As discussed previously, the bacterial membrane is negatively charged due to the 
presence of anionic phospholipids. As a result, cationic peptides can attach to these 
membranes for initial attachment by electrostatic means. Cationic AMPs with            
α-helical structure generally possess a net positive charge of atleast +2 and an 
amphipathic nature. However, the increase in cationic charge can also result in 
appreciable haemolytic activity. This is because for haemolysis, the peptides need to 
insert into the hydrophobic core perpendicular to the surface, forming 
transmembrane pores and an increased charge aids in more stronger electrostatic 
interaction [49]. However, there exists no simple correlation between peptide charge 
and its biological activity. Hence tailoring the number of cationic residues in the AMP 
to control the overall charge can help to maintain selectivity towards microbial 
membranes. Jiang et al studied the effect of net positive charge on the biological 
activity of AMPs by varying the ratio of charged residues in a 26-mer peptide. It was 
found that up to a threshold limit of net charge of +8, increasing the positive charge 
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did not affect the haemolysis significantly. However increasing the charge beyond +8 
dramatically increased the haemolytic potential of the peptides. Similarly the 
antimicrobial activity decreased with decrease in positive charge and it increased 
stepwise with an increase in positive charge. They also found that the number of 
positive charges was also equally important. Their results suggested that there exists 
a threshold charge amount for optimum selective antimicrobial activity [49]. Similar 
such studies have been performed by other research groups as well which reinforce 
the concept of a threshold cationic charge for biological activity for cationic AMP [50] . 
2.5.4.2 Secondary structure 
AMPs can form secondary structures due to different interactions between the amino 
acid residues. They can exist as alpha helical, beta sheet or in random coil. The ability 
to form a secondary structure in solution and self-associate is an important criterion 
in determining the antimicrobial activity of AMPs [51].  
Alpha helical peptides are one of the most common classes of AMPs. They consist of a 
right handed coil or spiral due to hydrogen bonding between every fourth amino acid 
residue. In many cases, the peptides lack an alpha structure in solution, but can form 
amphipathic alpha helix in the presence of a phospholipid bilayer. This property is 
highly essential for antimicrobial activity because the transition into a helix improves 
the amphipathic nature of the peptide. The hydrophilic chains of the α-helix further 
react electrostatically with negatively charged lipids and neutralize the excess positive 
charge and reduce peptide–peptide repulsion. Reduction in free energy comes from 
shielding the peptide bonds in the intramolecular H-bonds.  
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On the other hand, β-sheet peptides consist of parallel sheets of peptides linked by 
disulphide bridges. The disulphide bonds provide stability to the molecule and aid in 
bending of the molecule to penetrate through membranes. Hence it can be seen that 
the formation of a secondary structure (either α-helix or β-sheet) is crucial in the 
penetration of the AMP inside the microbial membrane. 
2.5.4.3 Hydrophobicity 
Hydrophobicity of peptides is another determinant of antimicrobial activity. This is 
because in membrane disruptive peptides, the final permeabilization of AMPs 
through bacterial membranes occurs via hydrophobic interactions between the 
peptide and the membrane. The peptide should be fairly soluble in water to enable 
quick transport to the microbial target. At the same time, it must also be able to 
interact with the hydrophobic region of the bilayer. It has been reported that there 
exists a threshold value of hydrophobicity beyond which the antimicrobial activity of 
AMPs decreases and haemolytic activity increases, probably owing to self-association 
of the peptide [52,53]. Hence maintaining the hydrophilic and hydrophobic balance in 
AMPs is highly essential for enhanced antimicrobial activity. 
2.5.5 Fatty acid conjugation of Antimicrobial peptides: 
As mentioned in the previous section, hydrophobicity has been found to be an 
essential factor in determining the activity of an AMP. Naturally several proteins such 
as myelin in eukaryotes [54] and murein lipoprotein of E.Coli [55] have been found to 
be covalently attached to fatty acids. Similarly several fatty acid conjugated peptides 
like daptomycin [56] and polymyxin have also been discovered in nature. These 
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lipopeptides have been found to possess excellent antibacterial and antifungal 
properties. 
Hence based on these natural lipopeptides, there has been recent interest in 
improving the activity of AMPs by chemical conjugation with fatty acids of varying 
chain length. Conjugation of fatty acids to hydrophilic peptides helps in improving the 
hydrophobicity of the peptide besides maintaining the hydrophobicity/hydrophilicity 
balance to form an amphiphile which is essential for antimicrobial activity.  
Chu-Kung et al found that the variation in chain length of saturated fatty acids 
conjugated to peptides caused a change in the antimicrobial activity of the peptides. 
The activity increased up to 16 carbon chain after which it decreased. This was 
attributed to the cut-off effect due to reduced lipid solubility and formation of 
peptide lipid complex [57] .   
Similar studies by Malina et al revealed that the peptides with shorter fatty acids (up 
to 12 Carbon) had better activity towards bacteria while the peptides with longer 
chain fatty acids (14 and 16 Carbon) had greater antifungal and haemolytic activity. 
Also, self association of the longer fatty acid chain peptides renders it difficult to 
penetrate through the more negatively charged membranes, thereby reducing their 
antibacterial activity [58].  
These studies indicate that a close relation exists between the chain length of the 
fatty acid conjugated to the peptide and their antimicrobial activity. This can be 
further attributed to the change in self-assembly behaviour of these fatty acid-
peptide conjugates owing to the different carbon chain length of the fatty acids. 
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Hence fatty acid conjugation to peptides can be used as an effective strategy to 




















3. DESIGN AND CHARACTERIZATION OF SYNTHETIC 
AMPHIPHILIC PEPTIDES - DHA-G3R6TAT-NH2 AND BA-G3R6TAT-
NH2 
 
3.1 Amphiphilic peptides design and background 
As discussed in the previous chapter, conjugation of fatty acid can improve the 
antimicrobial activity of peptides. In this study, the peptide chosen was a sequence 
from the basic membrane translocating portion of the Trans-activator of transcription 
(TAT) protein of the human immunodeficiency virus (HIV). This sequence is a 
positively charged peptide and is also rich in arginine (YGRKKRRQRRR). The TAT 
peptide is a cell penetrating peptide and has been found to translocate through the 
plasma membrane [59]. The TAT peptide has also been found to possess some 
antifungal property [60]. To this peptide sequence, six arginine residues were added 
to increase the hydrophilicity of the peptide, along with three glycine residues as 
spacer molecules to give the peptide sequence of GGGRRRRRRYGRKKRRQRRR 
(G3R6TAT-NH2). Arginine rich peptides have been found to penetrate through cells 
and an optimum number of 6 to 8 arginine residues were found to possess excellent 
cellular uptake properties [61]. Hence the addition of the arginine residues was 
believed to increase the cationic charge and cell penetrating ability of the TAT 
peptide sequence. 
Previously, cholesterol conjugation to G3R6TAT has been found to dramatically 
improve the antimicrobial activity of the unconjugated peptide without increasing its 
haemolytic activity [48]. This conjugate (CG3R6TAT) was able to self assemble into 
core/shell nanoparticles and was effective against a wide spectrum of Gram positive 
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bacteria and several strains of fungi too.  In vivo studies on rabbits showed that these 
nanoparticles were able to cross the blood brain barrier and suppress the growth of 
Cryptococcus neoformans [62].  
In this research work, however, the effects of fatty acid conjugation to G3R6TAT-NH2 
and the effects of degree of the fatty acid unsaturation on its antimicrobial activity 
were investigated. The fatty acid chosen was an omega-3 polyunsaturated fatty acid 
called docosahexaenoic acid (DHA), which is a 22 carbon fatty acid with 6 double 
bonds. The control fatty acid chosen for comparison was its saturated analogue 
behenic acid (BA) with the same number of carbon atoms as DHA. Docosahexaenoic 
acid is a major constituent of the central nervous system and is highly concentrated in 
the neuronal membranes inside the brain and retina. Dietary supplements of DHA in 
infants have been linked to their mental development [63]. DHA has also been used to 
treat peroxisomal diseases [64] and cardiovascular diseases. Also, since DHA can 
penetrate through the blood brain barrier and into tumours, it has been used as a 
carrier to deliver paclitaxel to different cancerous sites as well [65]. Due to these 
therapeutic effects, we believe that the conjugation of DHA to TAT peptide would 
render it to be a suitable antimicrobial agent for treating bacterial and fungal 
infections in the brain. 
3.2 Materials and methods 
3.2.1 Materials 
Anhydrous Dimethyl formamide (DMF) with 99.8 % purity, Dicyclohexyl carbodiimide 
(DCC) 1 M solution in Dichloromethane (DCM) and DHA were obtained from Sigma 
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Aldrich. N-hydroxysuccimide (NHS) was obtained from Thermo Scientific while ethyl 
ether was purchased from JT Baker. Peptide G3R6TAT-NH2 was obtained from GL 
Biochem, China and was of more than 95 % purity.  
α-cyano 4 hydroxycinnamic acid was purchased from Sigma (Singapore) as well. 
Phosphate buffer saline (PBS) at 10 X concentration was purchased from 1st Base 
(Malaysia). Cellulose acetate dialysis membrane was purchased from Spectra–Por and 
stored immersed in a preservative 1% sodium azide solution.  
3.2.2 Methods 
3.2.2.1 Solution phase synthesis of DHA-G3R6TAT-NH2 and BA-G3R6TAT-NH2 
Docosahexaenoic acid conjugated TAT peptide (DHA-G3R6TAT-NH2) and behenic acid 
conjugated TAT peptide (BA-G3R6TAT-NH2) were synthesized in batches of 30 
milligrams using the DCC/NHS coupling reaction. 
Briefly, 6.46 mg of NHS was weighed and was dissolved in 1 ml of DMF by vortex. This 
was followed by addition of 19.4 µl of DHA (Molar ratio of DHA: NHS: DCC = 1:1:1). To 
this, 56.2 µl of DCC in 1 M DCM was added finally. This was done to activate the acid 
group of DHA. The reaction vial was covered with aluminium foil since DHA is light 
sensitive. The activation was then allowed to occur for 24 hours with continuous 
stirring on a magnetic stirrer, under inert conditions, inside an Innovative 
Technologies glovebox. The next day, 30 mg of peptide G3R6TAT-NH2 was dissolved in 
1 ml of DMF and was added to the reaction mixture (Molar ratio of fatty acid: peptide 
= 5:1). The conjugation reaction was allowed to continue overnight for another two 
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days. On the third day, the reaction was arrested and the reaction mixture was 
further subjected to purification. 
The synthesis of BA-G3R6TATNH2 was quite similar to the synthesis of                      
DHA-G3R6TATNH2 as mentioned above, except that 19.2 mg of behenic acid was 
dissolved in 2 ml of DMF and added to the reaction mixture. The molar ratios 
between NHS, DCC, BA and peptide remained the same as above and the reaction 
mixture was allowed to react for two days after activation of behenic acid for one 





































































































































Figure 1: Chemical structures of (a) G3R6TAT-NH2, (b) DHA-G3R6TAT-NH2, (c) BA-G3R6TAT-NH2 
3.2.2.2 Purification by precipitation and dialysis 
The reaction mixture was added to around 40 ml of diethyl ether (anhydrous) with 
constant stirring, to precipitate the product and to remove the excess DHA/BA. The 
bottles were also washed with around 1 ml of DMF to remove excess product sticking 
to the walls of the glass vial and added to the precipitating solution. After 
precipitating for two hours, the solutions were subjected to centrifugation at 15000 
rpm, 24°C for 5 min. The supernatants were discarded and the centrifugation 
procedure was repeated by adding 40 ml of ether to the precipitates. The 
supernatants were discarded and the precipitates were dried in a vacuum oven for 
around 3 to 4 hours to remove the solvent completely. The samples were then 
freeze-dried overnight. The next day, the freeze-dried samples were weighed and 
dissolved in de-ionized water (DIW) to form a 5000 µg/ml solution. This was then 
subjected to dialysis against DIW using a cellulose acetate membrane with a 
molecular weight cut-off of 3500 kDa. The outside solution was replaced, every two 
hours for three times, on the first day and once on the second day. After two days of 


































































3.2.2.3 Matrix assisted Laser Desorption Ionization –Time of flight (MALDI-TOF) 
α-Cyano hydroxy-4-cinnamic acid (CHCA) is the matrix usually used for determining 
molecular weight of peptides and proteins. To prepare the matrix solution, around 10 
mg of CHCA was weighed on a weighing balance. Also, 10 ml of a 50:50 v/v solution of 
acetonitrile and DIW with 0.1 % Trifluoro acetic acid (TFA) was prepared. The CHCA 
was dissolved in 1 ml of the above solution using a vortex or sonicator to form a 
saturated solution. This matrix solution was then used for further analysis.  
For molecular weight determination, DHA-G3R6TAT-NH2 and BA-G3R6TAT-NH2 were 
dissolved in de-ionized water to form a 1000 µg/ml solution. 2 µl of CHCA matrix and 
2 µl of DHA-G3R6TAT-NH2 and BA-G3R6TAT-NH2 solutions were spotted on the   
MALDI-TOF ground steel target plate and mixed thoroughly by pipetting up and 
down. The samples were then allowed to dry in open atmospheric conditions to 
remove the solvent. The plate was then loaded on to the Bruker Autoflex II and the 
molecular weight was determined by targeting the sample with multiple shots of the 
N2 laser.  
3.2.2.3 Proton Nuclear Magnetic Resonance (1H – NMR) 
5 mg of DHA-G3R6TAT-NH2, BA-G3R6TAT-NH2 and G3R6TAT-NH2 were dissolved in 0.7 
ml of deuterated dimethyl sulfoxide (d-DMSO) each and 100 µl of DHA and 5 mg of 
BA were dissolved in 0.7 ml of deuterated chloroform (d-CHCl3) each. The samples 





3.2.2.4 Dynamic light scattering: 
10 mg of sample was dissolved in 2 ml of DIW and dialysed with a cellulose acetate 
membrane (having a molecular weight cut-off of 3500 Da) against DIW for two days. 
After two days, 1 ml of the solution was added to a disposable cuvette and the 
particle size of the nanoparticles formed was measured on a Zetasizer Nano (Malvern 
Instruments).  
3.2.2.5 Critical Micelle concentration Measurement 
10 mg of sample was dissolved in 2 ml of 1X Phosphate buffer saline (PBS) (1X PBS 
was prepared by mixing 4 ml of 10X PBS in 36 ml of DIW). Serial dilutions were 
prepared in 1X PBS starting from 5000 µg/ml to 1.2 µg/ml (5000, 2500, 1250,625, 
312.5, 156.2, 78.1, 39.05, 19.5, 9.7, 4.8, 2.4, 1.2 µg/ml). The control used was plain 1X 
PBS. Stock solution of a concentration of 0.6 mM of pyrene in acetone was prepared 
and this was further diluted to a concentration of 0.06 mM. 10 µl of this solution was 
added to a glass vial corresponding to each concentration. The acetone was allowed 
to evaporate for 15 min. 1 ml of each concentration was then added to the 
corresponding vials containing pyrene, to form a solution with a final concentration of 
0.6 µM of pyrene. The solutions were then allowed to incubate overnight on a shaker 
at 300 rpm. After 24 hours, the solutions were tested for the fluorescence of pyrene. 
The excitation spectra were recorded over a range of 300-360 nm with an emission 





3.3 Results and Discussion 
3.3.1 MALDI-TOF 
The unconjugated peptide has a theoretical molecular weight of 2667.1 Da while that 
of DHA and BA is 328.48 Da and 340.58 Da respectively. As can be seen from Figure 
2b, the MALDI-TOF spectrum showed a sharp peak corresponding to 2978.007 Da for 
the conjugate DHA-G3R6TAT-NH2, which is in close agreement with the theoretical 
molecular weight of 2997.58 Da, thereby confirming the successful conjugation of 
DHA to the peptide. Similarly a sharp peak observed at 2990.83 Da for the conjugate   
BA-G3R6TAT-NH2 (theoretical molecular weight of 2989.68 Da) as depicted in Figure 




Figure 2: MALDI-TOF spectrum of the (a) unconjugated peptide (G3R6TAT-NH2) - 2667 Da, (b) 
docosahexaenoic acid conjugated peptide (DHA-G3R6TAT-NH2) – 2978 Da and (c) behenic acid 








Proton NMR studies were done on the peptide, the fatty acids and the peptide-fatty 
acid conjugates. The peak corresponding to chemical shift of δ 5.3 for DHA-G3R6TAT-
NH2 was attributed to DHA (Figure 3a) while that corresponding to δ 0.9 – 1 for BA-
G3R6TAT-NH2 was attributed to BA (Figure 3b), thereby confirming the successful 









Figure 3:  
1
H-NMR of (a) DHA-G3R6TAT-NH2 and (b) BA-G3R6TAT-NH2 show successful conjugation of 
DHA and BA to G3R6TAT-NH2 respectively. 
 
3.3.3 Dynamic light scattering 
Both DHA-G3R6TAT-NH2 and BA-G3R6TAT-NH2 were found to form micelles and their 
particle size was determined by dynamic light scattering. 
Table 2: Particle size determination of nanoparticles formed by DHA-G3R6TAT-NH2 and BA-G3R6TAT-
NH2 
Peptide Z-Avg (nm) 
DHA-G3R6TAT-NH2 212 + 6  









3.3.4 Critical Micelle Concentration measurement 
The critical micelle concentration is an important parameter for determining the 
ability of AMPs to form micelles. Pyrene was used as a fluorescence probe, where the 
encapsulation of pyrene inside a hydrophobic environment entrapped inside the 
micelle shows less absorbance and thereby causes a shift in the excitation spectra. 
The maximum shift occurred at 338 nm, hence the ratio of intensity at 338 nm to the 
intensity at 334 nm was plotted as a function of the logarithm of concentration. The 
inflection point of the best fit lines drawn through the lower concentration data 
points and that of the higher concentration data points corresponded to the critical 
micelle concentration (CMC). It was found that DHA-G3R6TAT-NH2 had a CMC value of 
641 µg per ml (Figure 4a) while that of BA-G3R6TAT-NH2 was only around 71 µg per ml 
(Figure 4b). This indicates that the behenic acid conjugate (BA-G3R6TAT-NH2) formed 
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Figure 4:  Plot of I338/I334 vs logarithm of concentration of (a) DHA-G3R6TAT-NH2 and (b) BA-G3R6TAT-
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4. IN-VITRO STUDY OF THE BIOLOGICAL ACTIVITY OF THE 
AMPHIPHILIC PEPTIDES–DHA-G3R6TAT-NH2 and BA-G3R6TAT-
NH2 
 
The main purpose of this work is to develop an effective antimicrobial drug to target 
microbial infections without appreciable damage to normal host cells. The previous 
chapter dealt with the synthesis and characterization of the two amphiphilic peptides 
DHA-G3R6TAT-NH2 and BA-G3R6TAT-NH2. Having established the characteristics of 
these amphiphilic peptides, it then becomes important to test the biological efficacy 
of these amphiphilic peptides in specifically targeting bacteria and fungi. The 
minimum inhibitory concentration is the minimum concentration of the drug required 
to inhibit the visible growth of the micro-organism. Hence the MIC can be utilized as 
an indicator of antimicrobial activity. Often however, antimicrobial agents are 
associated with appreciable cytotoxicity effects as well. It is hence equally important 
that the antimicrobial agent causes damage to the micro organism without affecting 
normal host cells. This chapter elaborates on the various in vitro studies done to 
establish the specific activity of DHA-G3R6TAT-NH2 and BA-G3R6TAT-NH2 and their 
biological activities were compared.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
4.1 Materials and Methods 
4.1.1 Materials 
Tryptic Soy broth (TSB) and yeast mould broth powder were bought from BD 
Diagnostics and used to prepare the microbial growth medium according to the 
manufacturer’s instructions. LB agar was purchased from 1st Base. Ethanol (analytical 
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grade, 99%) and glutaraldehyde (synthesis grade, 50 % in H2O) were purchased from 
Sigma Aldrich. Gram positive bacteria Staphylococcus aureus (ATCC 29737) and 
Bacillus subtilis (ATCC 23857), Gram negative bacteria Escherichia coli (ATCC 25922) 
and Pseudomonas aeruginosa (ATCC 9027) and Yeast Candida albicans (ATCC 10231) 
were purchased from ATCC (USA) and reconstituted according to standard protocols. 
Red blood cells used in the haemolysis assay were obtained from rats maintained at 
the animal handling units of the Biomedical Research Centre, Singapore.  
4.1.2 Methods 
4.1.2.1 Preparation of Tryptic Soy Broth (TSB) medium 
30 grams of Tryptic Soy–Soya-Caesin Digest was dissolved in 1 l of de-ionized water. 
This was then autoclaved for 15 minutes. After this, the solution was allowed to cool 
and stored in the 4°C refrigerator for further use. 
4.1.2.2 Preparation of Yeast Mould broth 
21 grams of Yeast Mould broth was dissolved in 1 l of de-ionized water. This was then 
autoclaved for 15 minutes. After this, the solution was allowed to cool and stored in 
the 4°C refrigerator for further use. 
4.1.2.3 Inoculation of bacteria and fungi 
For all the bacteria used, 200 µl of bacteria were added to 5 ml of Tryptic Soy Broth 
medium and incubated at 37 °C with continuous shaking at 300 rpm around 5-6 hours 
prior to carrying out the Minimum Inhibitory Concentration Assay. For yeast alone, 
200 µl of yeast was added to 5 ml of yeast medium and incubated at room 
temperature with continuous shaking at 300 rpm overnight. 
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4.1.2.4 Minimum Inhibitory Concentration Assay 
Serial dilutions of DHA-G3R6TAT-NH2, BA-G3R6TAT-NH2 and G3R6TAT-NH2 were 
prepared in TSB (for bacteria) and in Yeast medium (for yeast) respectively, starting 
from a concentration of 500 µg/ml to 0.9 µg/ml (final concentrations after adding 
bacteria/fungi). 100 µl of each concentration was added to each of the wells of the 
96-well microtitre plate with 6 replicates for each concentration. After this, the 
bacterial/fungal solution initial loading was adjusted to an optical density reading of 
0.07 (equivalent to the McFarland 1 reference O.D. reading, which gives ~ 3 x 108 
CFU/mL bacteria suspension concentration [66]) on a TECAN-Safire II microtiter plate 
reader at a wavelength of 600 nm. This solution was then diluted 100 times to 
achieve an initial bacterial loading of ~ 3 x 106 CFU/mL for the MIC test. 100 µl of this 
bacterial/fungal solution was then added to each of the wells containing the peptide 
solutions. The control was plain bacteria/fungi without the peptide solution. Optical 
density readings at 600 nm were measured at 0 hours and after 18 hours of 
incubation on a shaker.  
4.1.2.5 Colony formation assay 
LB agar was melted in a microwave oven for around 5 min. Around 10 to 12 ml of 
agar was then added to each Petri dish to cover the entire surface and the agar was 
allowed to solidify. After this the plates were inverted.  
The minimum inhibitory concentration assay was repeated with concentration ranges 
of 4xMIC, 2xMIC, MIC, ½xMIC and Control. After 18 hours of incubation, the solutions 
from each replicates were transferred to micro-centrifuge tubes. The microbial 
solutions corresponding to each concentration were diluted with an appropriate 
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dilution factor. 20 µl of each dilution was added to an agar plate and spread with a 
cell spreader to cover the entire surface of the plate without damaging the solid agar. 
Each dilution plate was prepared in three replicates. The plates were then inverted 
and incubated for 24 hours after which the number of colonies was manually 
counted.  
4.1.2.6 Field Emission Scanning Electron Microscopy (FE-SEM) 
Solutions of DHA-G3R6TAT-NH2 of concentration 50 µg/ml (B.Subtilis), 100 µg/ml 
(S.aureus) were prepared in Tryptic Soy broth and 200 µg/ml (C.albicans) was 
prepared in yeast medium. Bacterial/fungal initial O.D. reading at 600 nm was 
adjusted to around 0.1-0.2. 1 ml of DHA-G3R6TAT-NH2 solution (at concentrations well 
above the respective MICs) was added to 1 ml of bacterial solution and allowed to 
incubate for one hour. At the end of one hour, the solution was centrifuged at 4000 
rpm for 5 min. The supernatant was discarded and then the sample was washed with 
PBS and centrifuged at 4000 rpm for 5 min. This was repeated three times. Following 
this, 1 ml of the sample was fixed by adding 2.5% glutaraldehyde solution for 15 min. 
The solution was then again centrifuged and washed with PBS two times and finally 
washed with DIW. The sample was then subjected to a series of ethanol washes (30%, 
50%, 70%, 95% and 100%) to dehydrate the sample. The sample was finally        
freeze-dried to remove all traces of water. The freeze-dried bacterial/fungal cells 
were mounted on a carbon strip and placed on the sample holder. The sample was 
then coated with platinum at 20 milliamperes for 20 seconds and imaged under a 




4.1.2.7 Haemolysis assay 
Solutions of DHA-G3R6TAT-NH2, BA-G3R6TAT-NH2 and G3R6TAT-NH2 were prepared in 
1X PBS and serial dilutions were done to obtain solutions in the concentration range 
of 500 µg/ml to 0.9 µg/ml (final concentrations after addition of blood solution), with 
300 µl in each tube.  The positive control was 0.1% Triton solution in 1X PBS which 
was assumed to cause 100 percent haemolysis and the negative control was 1X PBS 
which was assumed to caused 0 percent haemolysis. Rat blood cells stored at 4°C 
were taken out and allowed to reach the room temperature. 4% solution of blood in 
1X PBS was prepared and the initial O.D. reading at 576 nm of this solution with 0.1% 
Triton solution was measured. A value of around 0.5 – 0.6 indicated adequate cells 
available for haemolysis assay. Now, 300 µl of this blood solution was added to each 
concentration and the solutions were incubated for an hour at 37°C. After one hour, 
the solutions were centrifuged at 4°C at 1000 rpm for 5 min. 100 µl of the 
supernatant from each concentration was added to each well of a 96 well microtiter 
plate. Each concentration range corresponded to four replicates. The O.D. reading 
was then measured at 576 nm and the % hemolysis was calculated according to the 
formula: 
% Hemolysis = (O.D576(Sample) – O.D576(PBS)) / (O.D576(Triton) – O.D576(PBS)) 
4.2 Results and Discussion 
4.2.1 Minimum Inhibitory concentration assay 
The minimum inhibitory concentration assay is usually carried out to test the 
susceptibility of the target organism towards a particular drug. G3R6TAT-NH2,        
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DHA-G3R6TAT-NH2 and BA-G3R6TAT-NH2 were tested for their ability to inhibit the 
growth of various bacteria and fungi and their antimicrobial activity was compared. 
The MIC data is represented in Figures 5-9 and the minimum inhibitory concentration 
was attributed to the lowest threshold concentration range where the O.D. reading 
decreases after 18 hours compared to the initial zero hour reading. As can be 
observed from the figure 5, conjugation of DHA dramatically improved the activity of 
the unconjugated peptide against the pathogenic Staphylococcus aureus with a MIC 
value of as low as 31.25 µg/ml, which is almost an 8 fold decrease in MIC compared 
to that of the unconjugated peptide and the control peptide BA-G3R6TAT-NH2. One 
probable reason could be due to the fact that polyunsaturated fatty acids are quite 
selective towards Gram-positive bacteria especially S.aureus as reported by Knapp et 
al who observed that the activity of a 20 carbon fatty acid against S.aurues increased 
with the increase in number of double bonds in the fatty acid. They also found that 
the saturated long chain fatty acids were quite ineffective in killing S.aureus [67]. 
Similar studies have also indicated the selective action of polyunsaturated fatty acids 
towards Gram positive bacteria especially S.aureus [68].Hence the addition of DHA to 
the peptide could have increased its activity significantly towards S.aureus. 
Both the unconjugated peptide and DHA conjugated peptide were however found to 
be equally effective against B.Subtilis and C.albicans. 
Similarly, the activity of DHA-G3R6TAT-NH2 against Gram-positive bacteria was much 
higher when compared to BA-G3R6TAT-NH2 indicating that the presence of double 
bonds was necessary for targeting the Gram-positive bacteria. On the other hand, 
both the amphiphilic peptides exhibited similar activity against C. albicans.  
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 The less potent activity of the BA-conjugate in comparison to the DHA-conjugate 
could be attributed to its low CMC value as obtained in the previous chapter. Self–
association in solution has been found to reduce the activity of such antimicrobial 
amphiphilic peptides [47], [58]. This is probably due to the fact that the hydrophobic 
components needed to interact with the microbial membranes get entrapped within 
the micelle core and are no longer available for interaction with the membrane. Also 
the formation of stable micelles enhances the volume of the peptide thereby making 
it difficult for them to traverse through the membrane [58]. 
However, the unconjugated peptide and both the fatty acid conjugated peptides 
were found to be ineffective in targeting Gram-negative bacteria although DHA-
G3R6TAT-NH2 had a high value of MIC of 500 µg/ml against E.coli. This might be 
attributed to the fact that the Gram-negative bacteria have an additional outer cell 









Figure 5: Minimum inhibitory concentration determination of G3R6TAT-NH2 (250 µg/ml), DHA-
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Figure 6: Minimum inhibitory concentration determination of G3R6TAT-NH2 (15.6 µg/ml), DHA-























No of Hours 
































No of Hours 
































No of hours 














Figure 7: Minimum inhibitory concentration determination of G3R6TAT-NH2 (>500 µg/ml), DHA-
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Figure 8: Minimum inhibitory concentration determination of G3R6TAT-NH2 (>500 µg/ml), DHA-
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Figure 9: Minimum inhibitory concentration determination of G3R6TAT-NH2 (62.5 µg/ml), DHA-
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4.3.2 Colony formation Assay 
Many antimicrobial agents are only bacteriostatic and merely inhibit the growth of 
bacteria without killing them. Since the MIC values indicated the ability of DHA-
G3R6TAT-NH2 to inhibit the growth of gram positive bacteria and yeast more 
effectively in comparison to G3R6TAT-NH2 and BA-G3R6TAT-NH2, the colony formation 
assay was done to further test the efficacy of DHA-G3R6TAT-NH2 in destroying the 
pathogenic bacterial (Staphylococcus aureus) and fungal cells (C.albicans). The 
number of colonies remaining after treatment with DHA-G3R6TAT-NH2 was counted 
manually which corresponded to the number of live bacterial and fungal cells. The 
percentage (%) of cells killed was then calculated by using the formula: 
                                      
                                                       
                                    
                                     
                                        
It was found that DHA-G3R6TAT-NH2 was able to kill 99.9 % of the pathogenic 
microbes at concentrations corresponding to its MIC and above. This shows that DHA-
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Fig 10: Concentration dependant killing efficiency of DHA-G3R6TAT-NH2 against (a) S.aureus (b) 
C.albicans  
 
4.3.3 Field Emission Scanning Electron Microscopy (FE-SEM) 
The bacterial and fungal cells were viewed under the FE-SEM to observe the activity 
of DHA-G3R6TAT-NH2 on the morphology and physical attributes of the cells. As can 
be seen in the Figures 11-13, DHA-G3R6TAT-NH2 when treated at concentrations much 
higher than its MIC caused appreciable damage to the bacterial and fungal cell 
membranes in comparison to the untreated bacteria and fungi. This further confirms 
the ability of DHA-G3R6TAT-NH2 to kill the pathogenic bacteria and fungi. The 
extensive damage to the cell membrane as indicated by the cell debris also suggests 
that the lysis of the cell membrane might be a possible mechanism of action of DHA-
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Figure 11: FE-SEM images of B.subtilis (a) without and (b) with treatment with of DHA-G3R6TAT-NH2 








Figure 12: FE-SEM images of S.aureus (a) without and (b) with treatment with DHA-G3R6TAT-NH2 at a 










Figure 13: FE-SEM images of C.albicans (a) without and (b) with treatment with DHA-G3R6TAT-NH2 at 











4.3.4 Haemolysis assay 
The haemolysis assay was performed to investigate the selective activity of the DHA 
conjugated peptide towards microbial membranes. The unconjugated peptide and 
the DHA-peptide conjugate were found to possess negligible haemolytic activity at 
even the highest concentration tested (which was much higher than their MIC levels) 
while the BA-peptide conjugate was slightly haemolytic at the highest concentration 
tested. For example, DHA-G3R6TAT-NH2 doesn’t exhibit haemolysis even at a high 
concentration of 500 µg/ml which is much higher than its MIC against B.subtilis (15.6 
µg/ml), S.aureus (31.25 µg/ml) and C. albicans (62. 5 µg/ml). This thereby indicates 
that DHA-G3R6TAT-NH2 can be used a prospective antimicrobial agent without 
appreciable cytotoxicity effects. 
 
Figure 14: Plot of % Haemolysis vs concentration of G3R6TAT-NH2, DHA-G3R6TAT-NH2 and BA-
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5. CONCLUSIONS AND FUTURE WORK 
 
5.1 Conclusions 
Research in the field of infectious diseases therapy and drug discovery has been 
focussed on combating multi-drug resistance and developing alternative medicine. 
Antimicrobial peptides are a unique class of compounds which hold great promise as 
an alternative to conventional antibiotics. This study aims to design a potential 
therapeutic antimicrobial peptide drug to target different types of bacteria and fungi.  
A hydrophilic peptide (G3R6TAT-NH2), capable of crossing the blood brain barrier was 
conjugated to a hydrophobic long chain polyunsaturated fatty acid (docosahexaenoic 
acid) to form a peptide amphiphile, which is necessary for antimicrobial action. To 
study the effect of presence of double bonds in the fatty acid of the amphiphilic 
peptide, a similar saturated fatty acid (behenic acid) of the same carbon chain length 
as DHA was conjugated to G3R6TAT-NH2 and characterized.  
MALDI-TOF spectrum of both the conjugates DHA-G3R6TAT-NH2 and BA-G3R6TAT-NH2 
confirmed the successful conjugation of the peptide to the respective fatty acids. 1H-
NMR was used to further substantiate the formation of the two fatty acid-peptide 
conjugates.  
Pyrene was used as a probe to determine the critical micelle concentration of DHA-
G3R6TAT-NH2 and BA-G3R6TAT-NH2. The DHA conjugated peptide was found to have a 
significantly higher critical micelle concentration than the BA conjugated peptide, 
indicating that DHA-G3R6TAT-NH2 existed as free molecules in all the biological 
experiments performed in this study.  
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The addition of fatty acid to the peptide was done to improve the antimicrobial 
activity of the parent peptide. Several studies have been reported in literature where 
fatty acid conjugation has been used as a technique to improve antimicrobial activity 
of peptides. Most of these studies till now have used only saturated fatty acid 
conjugated peptides to compare the antimicrobial activity [57],[70]. This work 
however involved the novel use of a polyunsaturated fatty acid to compare the effect 
of unsaturation on the antimicrobial activity of fatty acid conjugated peptides. The 
minimum inhibitory concentration assay indicated that the conjugation of DHA to 
G3R6TAT-NH2 significantly increased its activity against S.aureus alone while 
maintaining similar activity against B.subtilis.  
Similarly, the presence of six double bonds of DHA was found to be crucial in the 
activity of DHA conjugated peptide against Gram-positive bacteria as BA-G3R6TAT-NH2 
displayed a much higher MIC value in comparison with DHA-G3R6TAT-NH2. However, 
both the amphiphilic peptides exhibited similar activity against C. albicans. 
All the three peptides G3R6TAT-NH2, DHA-G3R6TAT-NH2 and BA-G3R6TAT-NH2 failed to 
inhibit the growth of Gram-negative bacteria.  
The results from the haemolysis assay indicated the potential of DHA-G3R6TAT-NH2 to 
be used as a therapeutic as it was found to be non-haemolytic even at concentrations 
much higher than its MIC values, while BA-G3R6TAT-NH2 was found to be mildly 
haemolytic at higher concentrations.  
The ability of DHA-G3R6TAT-NH2 to function as a strong antibiotic was further proved 
by the colony formation assay which indicated that 99.9% of S.aureus and C.albicans 
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were killed at concentration levels of MIC and above. FE-SEM images also showed the 
damage of bacterial and yeast cells due to the action of DHA-G3R6TAT-NH2.  
Hence, the conjugate DHA-G3R6TAT-NH2 can be used as a therapeutic drug to treat 
infections caused by Gram-positive bacteria and fungi without appreciable 
cytotoxicity effects.  
5.2 Future work and recommendations 
This work was aimed at developing a prospective alternate form of medicine to treat 
bacterial and fungal infections. The in vitro studies indicated the ability of the 
developed synthetic drug to target pathogenic organisms like S.aureus and C.albicans. 
However, it needs to be seen, if the antimicrobial activity can be replicated in vivo. 
For this, the study of the ability of DHA-G3R6TAT-NH2 to treat microbial infections 
should be carried out in animal models. Also, this amphiphilic peptide was designed 
with molecules capable of crossing the blood brain barrier. Hence, bio-distribution 
studies of this drug in animals would indicate the potential of the DHA conjugated 
peptide to be used in combating brain infectious diseases as well. The stability of the 
drug in vivo is also an important criterion that needs to be monitored and 
investigated. Morever, FE-SEM studies seemed to indicate that the cell membrane of 
bacteria and fungi could be the target of action for DHA-G3R6TAT-NH2. Hence further 
validation of this possible mechanism of action of DHA-G3R6TAT-NH2 would aid in 
devising strategies to foresee probable microbial resistance development 
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